Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells

por Or, Chi-Hung R., Chang, Yachu, Lin, Wei-Cheng, Lee, Wee-Chyan, Su, Hong-Lin, Cheung, Muk-Wing, Huang, Chang-Po, Ho, Cheesang, Chang, Chia-Che
Publicado 2016

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

por Bao, Yi, Oguz, Gokce, Lee, Wee Chyan, Lee, Puay Leng, Ghosh, Kakaly, Li, Jiayao, Wang, Panpan, Lobie, Peter E., Ehmsen, Sidse, Ditzel, Henrik J., Wong, Andrea, Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang
Publicado 2020

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer

por Wang, Wenyu, Tang, Yen-An, Xiao, Qian, Lee, Wee Chyan, Cheng, Bing, Niu, Zhitong, Oguz, Gokce, Feng, Min, Lee, Puay Leng, Li, Baojie, Yang, Zi-huan, Chen, Yu-feng, Lan, Ping, Wu, Xiao-Jian, Yu, Qiang
Publicado 2021

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

por Ma, Shijun, Zhao, Yue, Lee, Wee Chyan, Ong, Li-Teng, Lee, Puay Leng, Jiang, Zemin, Oguz, Gokce, Niu, Zhitong, Liu, Min, Goh, Jian Yuan, Wang, Wenyu, Bustos, Matias A., Ehmsen, Sidse, Ramasamy, Adaikalavan, Hoon, Dave S. B., Ditzel, Henrik J., Tan, Ern Yu, Chen, Qingfeng, Yu, Qiang
Publicado 2022

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

por Ong, Li-Teng, Lee, Wee Chyan, Ma, Shijun, Oguz, Gokce, Niu, Zhitong, Bao, Yi, Yusuf, Mubaraka, Lee, Puay Leng, Goh, Jian Yuan, Wang, Panpan, Yong, Kylie Su Mei, Chen, Qingfeng, Wang, Wenyu, Ramasamy, Adaikalavan, Hoon, Dave S. B., Ditzel, Henrik J., Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang
Publicado 2022